Moderna Deal History & Licensing Activity
Moderna is a large biotech headquartered in US. Over the past three years, Moderna has been involved in 19 licensing and acquisition transactions, with a primary focus on mRNA (19 deals). The company currently has 1 active clinical trial, primarily in Infectious Disease.
Deals (12mo)
1
Active Trials
1
Top Modality
mRNA
Focus Area
Infectious Disease
Moderna Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Moderna in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| LNP patent license (settlement) | Genevant/Arbutus | mRNA | Approved | license | Mar 3, 2026 |
| mRNA-1018 | CEPI | mRNA | Phase 3 | collaboration | Dec 15, 2025 |
| mRNA-1018 | CEPI | mRNA | Phase 3 | collaboration |
Moderna Pipeline Focus
Therapeutic areas and modalities where Moderna is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Moderna Strategic Signals
Key indicators of Moderna's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Moderna Clinical Pipeline
Moderna has 1 active clinical trial across 1 development phase.
1
Phase 1
See How Your Asset Matches Moderna's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Infectious Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Infectious Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for infectious disease
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
mRNA Benchmarks
Upfront, milestone, and royalty benchmarks for mrna deals
Radiopharmaceuticals Benchmarks
Upfront, milestone, and royalty benchmarks for radiopharmaceuticals deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About Moderna Licensing & Deal Activity
Moderna is a large biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 19 deals over the past three years, Moderna ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Moderna include Infectious Disease (17 deals and trials), Oncology (3 deals and trials), Codev Deals (2 deals and trials), and Rare Disease (1 deal and trial). In terms of modality, Moderna has shown particular interest in mrna, radiopharmaceuticals, cell therapy.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Moderna and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Moderna's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.